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Abstract 
A large body of evidence supports a role of oxidative stress in Alzheimer disease (AD) and 
in cerebrovascular disease. A vascular component might be critical in the pathophysiology of AD, 
but there is a substantial lack of data regarding the simultaneous behavior of peripheral antioxidants 
and biomarkers of oxidative stress in AD and vascular dementia (VaD). 
Sixty-three AD patients, 23 VaD patients and 55 controls were included in the study. We 
measured plasma levels of water-soluble (vitamin C and uric acid) and lipophilic (vitamin E, 
vitamin A, carotenoids including lutein, zeaxanthin, β-cryptoxanthin, lycopene, α- and β-carotene) 
antioxidant micronutrients as well as levels of biomarkers of lipid peroxidation [malondialdehyde 
(MDA)] and of protein oxidation [immunoglobulin G (Ig G) levels of protein carbonyls and 
dityrosine] in patients and controls. 
With the exception of β-carotene, all antioxidants were lower in demented patients as 
compared to controls. Furthermore, AD patients showed significantly higher Ig G dityrosine content 
as compared to controls. AD and VaD patients showed similar plasma levels of plasma antioxidants 
and MDA as well as a similar Ig G content of protein carbonyls and dityrosine. We conclude that, 
independent of its nature – vascular or degenerative - dementia is associated with the depletion of a 
large spectrum of antioxidant micronutrients and with increased protein oxidative modification. 
This might be relevant to the pathophysiology of dementing disorders, particularly in light of the 
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Introduction 
Alzheimer disease (AD) constitutes the most prominent cause of dementia in the elderly 
and is clinically characterized by memory dysfunction, loss of lexical access, spatial and temporal 
disorientation and impairment of judgment. The biochemical mechanism of the pathogenesis of this 
disease is still unknown, but attention is given to the possible implication of oxidative stress in the 
development of AD. In AD [1, 2], as in other neurodegenerative disorders [3-5], an impaired energy 
metabolism has been shown, and the impaired mitochondrial function may lead to an increased free 
radical-related damage affecting critical cellular key components [1-5].  
An increase in DNA, lipid and protein oxidation products has been shown in blood and in 
post-mortem brain samples obtained from AD patients in comparison with controls [6]. A threefold 
increase in 8-oxo-dG has been found in mitochondrial DNA (mtDNA) isolated from cortical tissue 
of AD patients in comparison to nuclear DNA (nDNA) [7]. An increased 8-oxo-dG was also 
detected in nDNA from lymphocytes from AD patients as compared to control subjects [8]. This 
increase has been recently found to be inversely correlated to plasma levels of several antioxidant 
vitamins and micronutrients in AD patients [9].  
Higher ascorbic acid and β-carotene blood levels have been found in association with a better 
memory performance among subjects older than 65 years [10]. On the other hand, lower plasma vitamin 
C and E (Sinclair et al., 1998) as well as lower serum β-carotene and vitamin A [11] levels have been 
found in demented patients than in healthy controls. Plasma vitamin C levels have been shown to be 
lower in AD patients as compared to controls even in the presence of an adequate dietary vitamin C 
intake [12], and AD patients showed significantly lower cerebrospinal fluid levels of vitamin E than 
controls [13]. 
It is not known, however, whether AD is associated with a specific plasma antioxidant profile as 
has been shown for other non-neurodegenerative diseases [14], as studies conducted so far assessed only 
few antioxidants rather than a broader spectrum of water-soluble and lipophilic antioxidant vitamins and 
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micronutrients. In light of oxidative stress involvement in AD, the importance of the former both in 
aging [15] as well as in cardio- and cerebrovascular diseases [16,17] should be also considered: free 
radical hyperproduction associated to these different processes and disease states, when concomitant, 
may act synergistically or additively not only in deteriorating outcome, but also in precipitating a 
subclinical condition allowing AD to be uncovered [18]. This idea is substantially corroborated by 
recent findings showing a tight relationship, in animal models, between cerebral hypoperfusion, 
oxidative stress and amyloidogenesis [19, 20] as well by the relationship found between oxidative stress 
and the metabolism of homocysteine, a risk factor for both AD and vascular dementia (VaD) [21]. 
In the present study, peripheral levels of a broad spectrum of antioxidant micronutrients as 
well as of biomarkers of protein and lipid oxidation in patients with AD and VaD as compared to 
healthy controls were measured. Since circulating immunoglobulins are the second most prevalent 
serum protein, and the carbonyl content of immunoglobulins G (Ig G) has been previously shown to 
be sensitive to dietary antioxidant supplementation [22,23], we chose the evaluation of the carbonyl 
and dityrosine content in Ig G rather than total oxidized proteins.  
  
Subjects and Methods 
Subjects 
Eighty-six AD and VaD patients admitted to the Geriatric Day Hospital of the Department 
of Clinical and Experimental Medicine at the University Hospital of Perugia, Italy, were 
consecutively enrolled in the study. The diagnosis of AD or VaD was made on the basis of scores 
obtained to a full battery of cognitive, functional and behavioral tests as well as according to 
NINDS-AIREN [24] and NINCDS-ADRDA [25] criteria and to neuroradiologic findings. Sixty-
three patients were diagnosed as having AD (46 female, 17 male, 76.8 ± 6.9 years; MMSE 20,4 ± 3) 
and 23 patients as having VaD (14 female, 9 male, 78.0 ± 6.5 years; MMSE 19,8 ± 3). Patients were 
compared to 55 healthy controls (36 female, 19 male, 75.7 ± 7.3 years; MMSE 28,7 ± 1).  
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For nutritional status assessment, blood cell count, plasma albumin, prealbumin, cholesterol, 
and trigliycerides were measured. Data regarding dietary habits - as assessed by a food frequency 
questionnaire [26] -, the Body Mass Index (BMI) [weight Kg/(height m)2] and the Mini Nutritional 
Assessment (MNA) [27] were collected in all subjects.  
Subjects with anxiety or depression (evaluated by the Hamilton Anxiety Scale and the 
Geriatric Depression Scale, respectively) [28,29], history of smoking habit/alcohol abuse, major 
organ failure, malnutrition, dyslipidemia, alteration of protein metabolism as well as those taking 
iron or antioxidant supplements were excluded from the study. In order to exclude secondary causes 
of dementia, blood levels of vitamin B 12, folic acid and thyroid hormones were also determined. 
 
Blood sampling and antioxidant measurements 
The investigation conforms to the principles outlined in the Declaration of Helsinki.  
After obtaining informed consent from subjects or their relatives, patients and controls 
underwent blood drawing in a sodium heparin tube. Blood was immediately centrifuged and plasma 
was stored frozen at -80°C until analysis. In order to preserve vitamin C, an aliquot of plasma was 
deproteinized with 10% metaphosphoric acid and the supernatant kept at -80°C until analysis.  
Vitamin C and uric acid were measured by HPLC with electrochemical detection according to 
Kutnink et al. [30] with a Supelco C 18 column (250 mm x 4.6 mm i.d) and a Supelco C 18 guard 
column (20 mm x 4.6 mm i.d.).  
Vitamin A and vitamin E were measured, after extraction with ethanol and hexane, by HPLC 
with UV detection at 280 nm with a Waters Simmetry C 8 column (150 mm x 4.6 mm i.d.) [31]. 
Carotenoids including lutein, zeaxanthin, β-cryptoxanthin, lycopene, α- and β-carotene were 
detected at 450 nm using a Suplex, pKb 100 5-µm particles column (Supelco, Bellafonte, PA) 
according to Stahl et al. [32]. 
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Measurement of protein oxidation 
On thawing of plasma samples, Ig G were isolated from plasma and protein content was 
measured using bicinchoninic acid (BCA) method as previously described [22].  
Protein carbonyls were assessed by ELISA using the method of Carty et al. [22]. Absorbance 
was measured spectrophotometrically at 490 nm. Carbonyl content was calculated from the 
standard curve and expressed as nmol carbonyl per mg of Ig G. 
The analysis of protein dityrosine was performed by reverse-phase HPLC with UV detection 
at 240 nm connected in series with fluorescence at Ex 320 nm/Em 400 nm. Oxidised amino acid 
content of isolated Ig G was determined against a standard curve of 50-250 µM for dityrosine [33].  
 
Measurement of lipid peroxidation 
Plasma levels of malondialdehyde (MDA) were measured by HPLC as previously described 




Statistical analysis was performed with the program SPSS 11.0  (Chicago, IL). All data are 
presented as mean ± SD. Nonparametric 1-way analysis of variance (Kruskal Wallis) with the use 
of Dunn posttest was used for comparisons among groups. Linear regression was used for 
correlations between parameters. 
 
Results 
There was no significant difference between groups regarding age, years of education, BMI 
and MNA scores. Biochemical indexes of nutritional status and dietary intake did not differ among 
groups.  
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AD and VaD patients showed lower mean levels of plasma non-enzymatic antioxidants as 
compared to controls (Table 1). Since considering the ratio between plasma vitamin E/ vitamin A/ 
and total cholesterol did not alter results, data are expressed as total plasma levels of these 
compounds. 
AD and VaD patients showed significantly decreased plasma levels of the water-soluble 
vitamin C and uric acid, of the lipophilic vitamin E and vitamin A, and of the carotenoids lutein, 
zeaxanthin, β-cryptoxanthin, lycopene and α-carotene as compared to controls; among biomarkers 
of oxidative stress, only the content of dityrosine in Ig G was found to be significantly higher (p < 
0.01) in AD patients as compared to controls; although a trend towards higher levels of dityrosine 
was also observed in VaD subjects compared to controls (6.3 ± 1.7 µM in VaD patients vs. 5.1 ± 
1.6 µM in controls; p = 0.06), it did not reach statistical significance (Table 1). A significant inverse 
association was found between plasma lycopene and MDA levels (r = – 0.53, p < 0.0001).  
 
Discussion 
To our knowledge, there are no studies showing peripheral levels of a broad spectrum of 
both water-soluble and lipophilic antioxidant micronutrients as well as of biomarkers of free 
radical-induced damage to lipids and Ig G in patients with dementia. Our main finding is that 
plasma antioxidants are similarly depleted and Ig G oxidation products are similarly increased in 
AD and VaD. The potential implications of these results are related to the recently suggested 
importance of a vascular component in AD development [35-37]. In advanced age, as in the case of 
the patients included in our study, the differential diagnosis between AD and VaD is mainly made 
on the base of clinical features. This is due to the fact that the prevalence of unspecific subcortical 
vascular lesions seen on neuroimaging studies increases with advancing age and is high in AD [38]. 
For this reason, it is suggested the impaired oxidant/antioxidant balance observed in this study to be 
similar in AD and VaD patients might be at least partly related to the vascular component of both 
diseases [35-39]. On the other hand, the observation of a condition of oxidative stress occurring as a 
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pre-symptomatic feature in the process of neurodegeneration [40,41] has to be taken into account. 
In this prodromal stage of AD, called “mild cognitive impairment” [42], plasma antioxidants have 
been interestingly shown to be depleted to a similar extent as of in AD [43]. 
It is unlikely that antioxidant depletion in demented patients is due to malnutrition, based on 
thorough nutritional assessment performed in all subjects. Studies have suggested that demented 
subjects are malnourished - particularly in the final phase of the disease -, but lower plasma 
antioxidant levels have been recently shown in the early AD stages in well-nourished subjects 
[44,12].  
Non-enzymatic antioxidants, particularly dietary antioxidants such as vitamin C, vitamin E, 
β-carotene and polyphenols, exert positive effects on cognitive performance [45,2]. Therefore, it 
has been suggested that a balanced diet containing high amounts of antioxidant-rich fruits and 
vegetables might constitute an efficient way of decreasing the incidence and the prevalence of 
dementia in the elderly [46,47].  
The plasma non-enzymatic antioxidant profile of demented patients shows that the major 
components of the antioxidant defense system are affected in this condition. Vitamin C represents 
the major water-soluble antioxidant in human plasma and is able to prevent lipid peroxidation even 
in the presence of bleomycin-detectable free iron [48], known to play a pathophysiological role in 
metal-mediated oxidative stress in AD [49]. Vitamin E, on the other hand, is the most powerful 
chain-breaking antioxidant, found to be inversely associated with cognitive performance in the 
elderly [50].  
The antioxidant potential of carotenoids and retinol (vitamin A) is gaining increasing attention 
with respect to dementing disorders [44,9], as carotenoids such as lycopene have been shown to be 
efficient quenchers of singlet molecular oxygen and scavengers of peroxyl radicals [51]. High 
serum levels of carotenoids were found to be associated with less severe cerebral white matter 
lesions in the Rotterdam Scan Study [52]. In the present study, we found a strong inverse 
association between plasma levels of lycopene and MDA. Interestingly, plasma levels of lycopene 
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in AD patients were also found to be inversely associated with DNA oxidative damage as assessed 
by the content of 8-oxo-dG in nDNA of lymphocytes [9].   
Among biomarkers of oxidative stress, Ig G levels of dityrosine but not of carbonyls were 
shown to be significantly higher in demented patients as compared to controls. Increased brain 
protein oxidation has been found in AD as well as in other neurodegenerative disorders [53]. 
In one study, the total amount of oxidatively modified proteins measured by HPLC was found 
to be increased in plasma from AD patients as compared to controls [54]. In the present study, the 
choice of evaluating the carbonyl and dityrosine content in Ig G rather than total oxidized proteins 
was based upon a number of considerations. First of all, and bearing in mind that targets of protein 
oxidation are determined by proximity to the source of reactive oxygen species, relative 
concentration and size, circulating immunoglobulins are the second most prevalent serum protein. 
Albumin carries lipids, thereby rendering difficult the discrimination between primary and 
secondary oxidation. Furthermore, the carbonyl content of Ig G has been previously shown to be 
sensitive to dietary antioxidant supplementation [22,23]. Finally, Ig G have a half life of 15 days, 
making them a good temporal indicator of oxidative stress. While no studies on dityrosine in serum 
or plasma of patients with AD are known yet, dityrosine has been found in plaques from AD 
patients [55]. In one study, dityrosine and 3-nitrotyrosine levels were found to be elevated in the 
hippocampus and neocortical regions of AD brains and in ventricular cerebrospinal fluid, reaching 
quantities five- to eight-fold greater than mean concentrations in brain and ventricular cerebrospinal 
fluid of cognitively normal subjects [56]. In the same study, interestingly, also uric acid - a 
proposed peroxynitrite scavenger - was decreased globally in the AD brains and ventricular 
cerebrospinal fluid.  
The results of this study show that dementia, apparently independent of its vascular or 
degenerative origin, is associated with the depletion of a large spectrum of antioxidant 
micronutrients and with increased protein oxidative modification. This might be relevant to the 
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pathophysiology and prevention of dementing disorders, particularly in light of the recently 
suggested importance of the vascular component in AD development. 
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Table 1. Plasma levels of vitamin C, uric acid, vitamin A, vitamin E, lutein, zeaxanthin, β-
cryptoxanthin, lycopene, α-carotene, β-carotene, levels of protein carbonyls and dityrosine in 
immunoglobulin G, and plasma levels of malondialdehyde in Alzheimer Disease patients, Vascular 
Dementia patients and in controls. Data are given in mean ± S.D. 
 
Compound (units) Alzheimer Disease 
(n = 63) 
Vascular Dementia 
(n = 23) 
Controls 
(n = 55) 
Vitamin C (µmol/L) 25.9 ± 8.9 *** 26.6 ± 11.3 *** 52.4 ± 16.4 
Uric acid (µmol/L) 199.0 ± 52.0 *** 193.6 ± 46.6 *** 312.9 ± 82.3 
Vitamin A (µmol/L) 2.0 ± 0.38 *** 2.0 ± 0.37 *** 2.7 ± 0.3 
Vitamin E (µmol/L) 37.8 ± 5.8 *** 36.4 ± 4.7 *** 50.2 ± 10.2 
Lutein (µmol/L) 0.36 ± 0.18 *** 0.34 ± 0.1 *** 0.67 ± 0.35 
Zeaxanthin (µmol/L) 0.06 ± 0.02 *** 0.07 ± 0.05 *** 0.15 ± 0.08 
β-Cryptoxanthin (µmol/L) 0.17 ± 0.14 *** 0.17 ± 0.12 ** 0.41 ± 0.42 
Lycopene (µmol/L) 0.61 ± 0.22 * 0.61 ± 0.23 * 0.78 ± 0.36 
α-Carotene (µmol/L) 0.06 ± 0.03 ** 0.06 ± 0.03 ** 0.12 ± 0.12 
β-Carotene (µmol/L) 0.57 ± 0.28 0.53 ± 0.27 0.55 ± 0.34 
Protein carbonyls 
(µmol/L) 
4.3 ± 1.6 3.7 ± 1.4 4.0 ± 1.5 
Dityrosine (µmol/L) 7.3 ± 2.4 * 6.3 ± 1.7 5.1 ± 1.6 
Malondialdehyde 
(µmol/L) 
0.25 ± 0.07 0.24 ± 0.11 0.28 ± 0.14 
 
 
*p < 0.01,  ** p < 0.001,  *** p < 0.0001 vs controls 
 
